help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on October 9, 2009
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-1308
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
94/11/4517    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Triolo, T. M.
Right arrow Articles by Barker, J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Triolo, T. M.
Right arrow Articles by Barker, J. M.
Related Collections
Right arrow Autoimmunity

Submitted on June 22, 2009
Accepted on August 27, 2009

Homozygosity of the Polymorphism MICA5.1 Identifies Extreme Risk of Progression to Overt Adrenal Insufficiency among 21-Hydroxylase Antibody-Positive Patients with Type 1 Diabetes

Taylor M. Triolo, Erin E. Baschal, Taylor K. Armstrong, Carrie S. Toews, Pamela R. Fain, Marian J. Rewers, Liping Yu, Dongmei Miao, George S. Eisenbarth, Peter A. Gottlieb, and Jennifer M. Barker*

Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Health Science Center, Aurora, CO 80045

* To whom correspondence should be addressed. E-mail: jennifer.barker{at}ucdenver.edu.

Context: Autoimmunity associated with Addison's disease (AD) can be detected by measuring 21-hydroxylase (21OH) autoantibodies. Subjects with type 1 diabetes (T1D) are at increased risk for AD. Genetic factors including HLA-DRB1*0404 and MICA have been associated with AD in populations with and without T1D.

Objective: The objective of the study was to examine the effect of the MICA5.1 allele in subjects with 21OH autoantibodies on progression to AD.

Design: Two components were used: 1) a cross-sectional study with subjects with AD identified and enrolled from September 1993 to November 2008 and 2) a cohort study prospectively following up patients with T1D who screened positive for 21OH autoantibodies.

Setting: Subjects were identified from the Barbara Davis Center and through the National Adrenal Diseases Foundation.

Patients: Sixty-three subjects with AD were referred through the National Adrenal Diseases Foundation (AD referrals). Sixty-three subjects with positive 21OH antibodies from the Barbara Davis Center were followed up for progression to AD, and 11 were diagnosed with AD (progressors).

Results: Seventy-three percent of progressors (eight of 11) and 57% of AD referrals (36 of 63) were MICA5.1 homozygous (P = ns). Overall, 59% of patients with AD (44 of 74) were MICA5.1/5.1 compared with 17% of nonprogressors (nine of 52) (P < 0.0001) and 19% of normal DR3/4-DQB1*0302 controls (64 of 336) (P < 0.0001).

Conclusions: Identifying extreme risk should facilitate monitoring of progression from 21OH antibody positivity to overt AD. The HLA-DR3/0404 genotype defines high-risk subjects for adrenal autoimmunity. MICA5.1/5.1 may define those at highest risk for progression to overt AD, a feature unique to AD and distinct from T1D.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society